Alemtuzumab (Campath®, MabCampath®) is a humanised monoclonal antibody against the CD52 antigen expressed on lymphocytes. In 2001 Campath was approved for the treatment of patients with chronic lymphocytic leukaemia who have failed previous chemotherapy with alkylating agents and fludarabine. It is currently being developed by Genzyme Corporation and Schering AG for a range of other indications including non-Hodgkin's lymphoma and multiple sclerosis. Campath was originally developed in the laboratory of Herman Waldmann at Cambridge University. The BioAnalab founders played a key role in its successful clinical and commercial development, including the development and validation of analytical tests used to support its regulatory approval. BioAnalab has licensed diagnostic rights to CD52 antibodies throughout Europe and the Middle East. It supplies the only authentic reagents for detection and measurement of the Campath antigen through its marketing partner AbD Serotec Ltd (www.serotec.com). Specialised know-how and unique reagents have been exclusively licensed to BioAnaLab. The company provides unique tests for: CD52 antigen Campath levels in blood Antiglobulin response to Campath